Search

Juan A. Torres

Examiner (ID: 18450, Phone: (571)272-3119 , Office: P/2634 )

Most Active Art Unit
2634
Art Unit(s)
2631, 2634, 2636, 2611
Total Applications
1774
Issued Applications
1502
Pending Applications
75
Abandoned Applications
208

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 16993247 [patent_doc_number] => 20210231667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-29 [patent_title] => METHOD FOR DETECTING OR MONITORING PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/019086 [patent_app_country] => US [patent_app_date] => 2020-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17019086 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/019086
METHOD FOR DETECTING OR MONITORING PROSTATE CANCER Sep 10, 2020 Abandoned
Array ( [id] => 20492657 [patent_doc_number] => 12534520 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-27 [patent_title] => YKL-40-targeting human monoclonal antibody [patent_app_type] => utility [patent_app_number] => 17/753682 [patent_app_country] => US [patent_app_date] => 2020-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 40 [patent_no_of_words] => 2451 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753682 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/753682
YKL-40-targeting human monoclonal antibody Sep 6, 2020 Issued
Array ( [id] => 16878041 [patent_doc_number] => 11028174 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-06-08 [patent_title] => Bifunctional molecules targeting PD-L1 and TGF-b [patent_app_type] => utility [patent_app_number] => 17/006517 [patent_app_country] => US [patent_app_date] => 2020-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 27 [patent_no_of_words] => 11793 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 127 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17006517 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/006517
Bifunctional molecules targeting PD-L1 and TGF-b Aug 27, 2020 Issued
Array ( [id] => 16977668 [patent_doc_number] => 20210221905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-22 [patent_title] => ANTI-CD73 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/005051 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17005051 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/005051
Anti-CD73 antibodies Aug 26, 2020 Issued
Array ( [id] => 16720144 [patent_doc_number] => 20210087291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => COMBINATION THERAPY OF T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES AND PD-1 AXIS BINDING ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 16/988540 [patent_app_country] => US [patent_app_date] => 2020-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86477 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16988540 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/988540
Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists Aug 6, 2020 Issued
Array ( [id] => 17929825 [patent_doc_number] => 20220324950 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => IMMUNE CHECKPOINT INHIBITOR, THERAPEUTIC AGENT FOR IMMUNE CHECKPOINT-RELATED DISEASE, IMMUNOSUPPRESSANT, ANTI-FIBRONECTIN ANTIBODY OR DERIVATIVE THEREOF, FIBRONECTIN ANALOG, KIT FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF, AND METHOD FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF [patent_app_type] => utility [patent_app_number] => 17/634424 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634424 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/634424
IMMUNE CHECKPOINT INHIBITOR, THERAPEUTIC AGENT FOR IMMUNE CHECKPOINT-RELATED DISEASE, IMMUNOSUPPRESSANT, ANTI-FIBRONECTIN ANTIBODY OR DERIVATIVE THEREOF, FIBRONECTIN ANALOG, KIT FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF, AND METHOD FOR DETECTING FIBRONECTIN OR PARTIAL PROTEIN THEREOF Aug 5, 2020 Pending
Array ( [id] => 17945815 [patent_doc_number] => 20220332832 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS [patent_app_type] => utility [patent_app_number] => 17/631378 [patent_app_country] => US [patent_app_date] => 2020-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43296 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631378 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/631378
COMBINED CANCER THERAPY OF ANTI-GALECTIN-9 ANTIBODIES AND CHEMOTHERAPEUTICS Aug 2, 2020 Pending
Array ( [id] => 16762377 [patent_doc_number] => 20210107958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => GLYPICAN EPITOPES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/939729 [patent_app_country] => US [patent_app_date] => 2020-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16939729 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/939729
GLYPICAN EPITOPES AND USES THEREOF Jul 26, 2020 Abandoned
Array ( [id] => 17982631 [patent_doc_number] => 20220348667 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => Specific ACKR2 Modulators for Use in Therapy [patent_app_type] => utility [patent_app_number] => 17/620281 [patent_app_country] => US [patent_app_date] => 2020-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620281 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/620281
Specific ACKR2 Modulators for Use in Therapy Jul 14, 2020 Pending
Array ( [id] => 17853123 [patent_doc_number] => 20220283165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => Methods of Enhancing Immunogenicity of Cancers [patent_app_type] => utility [patent_app_number] => 17/625264 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17544 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625264 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/625264
Methods of Enhancing Immunogenicity of Cancers Jul 9, 2020 Pending
Array ( [id] => 17828516 [patent_doc_number] => 20220265820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => TUMOR IMMUNOTHERAPY USING SINDBIS VIRAL VECTORS AND AGONIST MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/625326 [patent_app_country] => US [patent_app_date] => 2020-07-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625326 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/625326
TUMOR IMMUNOTHERAPY USING SINDBIS VIRAL VECTORS AND AGONIST MONOCLONAL ANTIBODIES Jul 7, 2020 Pending
Array ( [id] => 16596660 [patent_doc_number] => 20210023191 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => VACCINE COMPOSITIONS COMPRISING TRYPTOPHAN 2,3-DIOXYGENASE OR FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 16/922604 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25178 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922604 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/922604
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof Jul 6, 2020 Issued
Array ( [id] => 16420464 [patent_doc_number] => 20200345662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => MUSCULAR ATROPHY-INDUCING AGENT USING HYPOMETABOLISM-INDUCING SUBSTANCE T1AM, AND USE THEREOF IN TREATING MUSCULAR HYPERTROPHY [patent_app_type] => utility [patent_app_number] => 16/922432 [patent_app_country] => US [patent_app_date] => 2020-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8717 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16922432 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/922432
MUSCULAR ATROPHY-INDUCING AGENT USING HYPOMETABOLISM-INDUCING SUBSTANCE T1AM, AND USE THEREOF IN TREATING MUSCULAR HYPERTROPHY Jul 6, 2020 Abandoned
Array ( [id] => 18590256 [patent_doc_number] => 11739139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-29 [patent_title] => Monoclonal antibodies against Claudin-18 for treatment of cancer [patent_app_type] => utility [patent_app_number] => 16/919969 [patent_app_country] => US [patent_app_date] => 2020-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 64 [patent_no_of_words] => 38062 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 113 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919969 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/919969
Monoclonal antibodies against Claudin-18 for treatment of cancer Jul 1, 2020 Issued
Array ( [id] => 18361500 [patent_doc_number] => 20230143091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-11 [patent_title] => COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/620036 [patent_app_country] => US [patent_app_date] => 2020-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25696 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17620036 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/620036
Compositions Jun 18, 2020 Issued
Array ( [id] => 16555804 [patent_doc_number] => 20210000952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF [patent_app_type] => utility [patent_app_number] => 16/904511 [patent_app_country] => US [patent_app_date] => 2020-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16904511 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/904511
Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof Jun 16, 2020 Issued
Array ( [id] => 17775064 [patent_doc_number] => 20220241413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => COMBINATION THERAPIES USING CD-38 ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/617811 [patent_app_country] => US [patent_app_date] => 2020-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617811 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/617811
COMBINATION THERAPIES USING CD-38 ANTIBODIES Jun 8, 2020 Pending
Array ( [id] => 17762664 [patent_doc_number] => 20220236276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => METHODS FOR MODULATING A TREATMENT REGIMEN [patent_app_type] => utility [patent_app_number] => 17/616519 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13414 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616519 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/616519
METHODS FOR MODULATING A TREATMENT REGIMEN Jun 2, 2020 Pending
Array ( [id] => 18642420 [patent_doc_number] => 11766473 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a deliver system [patent_app_type] => utility [patent_app_number] => 16/881580 [patent_app_country] => US [patent_app_date] => 2020-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 6807 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16881580 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/881580
Therapeutic cancer vaccine containing tumor-associated neoantigens and immunostimulants in a deliver system May 21, 2020 Issued
Array ( [id] => 17913266 [patent_doc_number] => 20220315661 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/609359 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -45 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609359 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/609359
DOSAGE REGIMENS FOR A COMBINATION OF ANTI-DR5 ANTIBODIES FOR USE IN TREATING CANCER May 10, 2020 Abandoned
Menu